Drug intelligence / Profile preview

COVID19-0001-USR

Development stage: Phase 2
Lead developer: Merck
Administration: Inhalation

Overview

COVID19-0001-USR is an investigational drug studied for the treatment of mild to moderate SARS-CoV-2 (COVID-19) infection in outpatient settings. The drug was evaluated in clinical trials to determine its efficacy and safety when administered via nebulization. Specific details regarding its mechanism of action, molecular class, or active ingredient have not been disclosed in publicly available sources. Its development appears focused on early intervention for non-hospitalized patients with confirmed COVID-19 infection[1][2][3].

Brand names: COVID19-0001-USRCOVID-19-0001-USRCOVID 19-0001-USR
Other names: COVID19-0001-USRCOVID-19-0001-USRCOVID 19-0001-USR

Beyond the preview

Go deeper on COVID19-0001-USR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVID19-0001-USR.

Explore the full profile